BETHESDA, MD, May 29, 2014 — Scientists and consultants from Evidera, a global leader in health economics, outcomes research, market access, data analytics and epidemiology solutions, will present more than 40 papers — the highest of any attending company — at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting in Montreal, Quebec, Canada.
Topics include patients’ perspectives, rare diseases and innovative methodologies to support market access:
- Kevin Marsh, PhD, senior research scientist, European director, and Tereza Lanitis, MSc, research associate: “Understanding and Modeling Business Decisions in Market Access and Reimbursement Using Multi-Criteria Decision Analytics Techniques”
- Margaret Vernon, PhD, senior research scientist, European director: “PRO and OBSRO Measurement in Rare Disease Clinical Trials – Emerging Good Practices”
- Alexandra Ward, PhD, MRPharmS, senior research scientist, and Kathleen Wyrwich, PhD, senior research leader: “Big Data and Little Diseases: Meeting the Challenges for Rare Disease Outcomes Research”
“It’s an honor to showcase our breadth and depth of experience at ISPOR, ” said Jon Williams, Evidera president and CEO. “We are making considerable investments in novel methods and solutions, as well as the scientific leadership necessary to help life science organizations successfully optimize the value and market access of their products. We look forward to sharing some of these new and exciting accomplishments with our clients, colleagues and friends.”
View a full list of workshops, short courses, podiums and posters, and visit booth 70 to learn more about Evidera.
Evidera, a wholly owned subsidiary of Symphony Technology Group, is one of the preeminent commercial entities analyzing effectiveness, establishing evidence and substantiating the value of treatments within the global health industry through its market-leading portfolio of health economics, outcomes research, market access, data analytics and epidemiology services. Evidera partners with life sciences organizations worldwide to optimize the market access and commercial success of their products by leveraging unparalleled knowledge of the global payer and regulator landscape and by developing, capturing and communicating the clinical and economic evidence that clients require to successfully market their products. Our research and consulting services are driven by world-class science and thought leadership and leverage a unique combination of capabilities.